Accelerated Phase Chronic Myelogenous Leukemia Completed Phase 2 Trials for Fludarabine (DB01073)

IndicationStatusPhase
DBCOND0028985 (Accelerated Phase Chronic Myelogenous Leukemia)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01529827Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTreatment
NCT01175785Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic MalignanciesTreatment
NCT01427881Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesTreatment
NCT00860574Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic LeukemiaTreatment
NCT00049504Fludarabine Phosphate, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Total-Body Irradiation, and Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerTreatment
NCT01056614Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid MalignanciesTreatment
NCT003815503-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaTreatment